NasdaqCM - Nasdaq Real Time Price USD

ProQR Therapeutics N.V. (PRQR)

1.9100

+0.1200

+(6.70%)

At close: June 6 at 4:00:00 PM EDT

1.9910

+0.08

+(4.24%)

After hours: June 6 at 5:16:09 PM EDT

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will present at two upcoming scientific conferences: the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place May 13-17, 2025, in New Orleans, Louisiana and the TIDES USA 2025: Oligonucl

GlobeNewswire 27 days ago

PRQR
+6.70%
New Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR)

Shareholders in ProQR Therapeutics N.V. ( NASDAQ:PRQR ) may be thrilled to learn that the analysts have just delivered...

Simply Wall St. 30 days ago

PRQR
+6.70%
ProQR Announces First Quarter 2025 Operating and Financial Results

Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer and Chief Medical Officer€ 132.4 million cash and cash equivalents as of end Q1 providing runway into mid-2027, plus additional potential milestones from Lilly partnership LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) --

GlobeNewswire last month

PRQR
+6.70%
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform today announced that Company management is scheduled to present at the Citizens (JMP) Life Sciences Conference in New York City on Thursday, May 8 at 11:30 AM EDT. A live webcast of the Company’s fireside chat will be available from the “I

GlobeNewswire last month

PRQR
+6.70%
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the Annual General Meeting (AGM) of Shareholders will take place on Tuesday, June 3, 2025 at 1530 CEST at the offices of Allen Overy Shearman Sterling LLP, in Amsterdam, the Netherlands. All relevant documents and informa

GlobeNewswire last month

PRQR
+6.70%
ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Steve Seedhouse assumed coverage of ProQR Therapeutics (PRQR) with an Overweight rating and $8 price target ProQR is a leader in RNA editing and the initial biomarker data for its first program targeting bile acid transporter in Q4 will be an “important catalyst,” the analyst tells investors in a research note. Cantor views the company as a “pure play” on RNA editing. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. T

TipRanks last month

PRQR
+6.70%
ProQR Therapeutics initiated with an Outperform at Evercore ISI

Evercore ISI initiated coverage of ProQR Therapeutics (PRQR) with an Outperform rating and $5 price target ProQR represents a “true” biotech investment given its early-stage, emerging technology with “a plethora of potential applications,” ovel first in class targets and a wide array of strategic optionality for the company, but over the last few years investors have increasingly focused on derisked targets and indications, which is why the stock is trading at cash despite what the firm calls “s

TipRanks last month

PRQR
+6.70%
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the appointment of Dennis Hom as Chief Financial Officer (CFO) and Cristina Lopez Lopez, MD, PhD, as Chief Medical Officer (CMO). These key leadership appointments support the advancement of the Company’s Axiomer platfor

GlobeNewswire last month

PRQR
+6.70%
ProQR Therapeutics Full Year 2024 Earnings: Misses Expectations

ProQR Therapeutics ( NASDAQ:PRQR ) Full Year 2024 Results Key Financial Results Revenue: €19.5m (up 196% from FY 2023...

Simply Wall St. 2 months ago

PRQR
+6.70%
ProQR Announces Year End 2024 Operating and Financial Results

Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expects up to four clinical data readouts in 2025 and 2026 across multiple programs, highlighted by first clinical data for AX-0810 anticipated in Q4 2025€ 149.4 million cash and cash equivalents as of end of 2024, providing runway into mid-2027, plus additional potential milestones from Lilly partnershi

GlobeNewswire 2 months ago

PRQR
+6.70%
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) largest shareholders are individual investors with 60% ownership, institutions own 17%

Key Insights ProQR Therapeutics' significant individual investors ownership suggests that the key decisions are...

Simply Wall St. 3 months ago

PRQR
+6.70%
Is There An Opportunity With ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 37% Undervaluation?

Key Insights Using the 2 Stage Free Cash Flow to Equity, ProQR Therapeutics fair value estimate is US$4.13 ProQR...

Simply Wall St. 5 months ago

PRQR
+6.70%
ProQR Therapeutics announces $8.1M in new funding from RSRT

ProQR Therapeutics (PRQR) announced an expansion of its collaboration with the Rett Syndrome Research Trust, RSRT. Building on the initial $1 million research grant announced in January 2024, the expanded partnership includes an additional $8.1 million in funding from the RSRT, for a total of $9.1 million. The funding will support the advancement of AX-2402 into clinical trials. The additional $8.1 million in funding will enable ProQR to accelerate work on RNA editing approaches tailored to the

TipRanks 5 months ago

PRQR
+6.70%
ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced an expansion of its collaboration with the Rett Syndrome Research Trust (RSRT). Building on the initial $1 million research grant announced in January 2024, the expanded partnership includes an additional $8.1 million in

GlobeNewswire 5 months ago

PRQR
+6.70%
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the appointment of Dr. Peter Beal, a professor of Chemistry at the University of California, Davis, as Chief ADAR Scientist. Dr. Beal, one of the top experts in ADAR and RNA biology and chemistry, has been a long-term col

GlobeNewswire 5 months ago

PRQR
+6.70%
ProQR Therapeutics price target raised to $8 from $5 at JMP Securities

JMP Securities analyst Jonathan Wolleben raised the firm’s price target on ProQR Therapeutics (PRQR) to $8 from $5 and keeps an Outperform rating on the shares as part of a broader note on Biotechnology. The firm highlighted key upcoming catalysts for its coverage universe over the next 12 months, ahead of what is shaping up to be a “busy” 2025, and noted that it still has several events expected between now and the end of the year which could provide a reason for “cheer” this holiday season. Pu

TipRanks 5 months ago

PRQR
+6.70%
ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that the Company will host a virtual Analyst and Investor Event on Wednesday, December 11, 2024 from 10:00 am until approximately 12:30 pm EST, including an Analyst Q&A session with members of the ProQR Management Team. During the event, ProQR will highlight its proprietary Axiomer™ AD

GlobeNewswire 5 months ago

PRQR
+6.70%
ProQR Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

ProQR Therapeutics ( NASDAQ:PRQR ) Third Quarter 2024 Results Key Financial Results Revenue: €3.98m (up 191% from 3Q...

Simply Wall St. 6 months ago

PRQR
+6.70%
ProQR Therapeutics sees cash runway into mid-2027

At September 30, 2024, ProQR held cash and cash equivalents of EUR 89.4 million, compared to EUR 118.9 million cash and cash equivalents at December 31, 2023. Net cash used in operating activities during the three-month period ended September 30, 2024 was EUR 5.7 million, compared to EUR 7.5 million used for the same period last year. During the first three quarters of 2024, the Company achieved certain milestones in the collaboration agreement with Eli Lilly amounting to $5.5 million. In Octobe

TipRanks 6 months ago

PRQR
+6.70%
ProQR Announces Third Quarter 2024 Operating and Financial Results

AX-0810 targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to host virtual Investor and Analyst Event in December to highlight translational data and clinical plans for AX-0810, as well as AX-1412, targeting B4GALT1 for cardiovascular diseases, and progress made across the Axiomer platform€89.4 million cash and cash equivalents as of end of Q3, plus $82.1 million gross proceeds from October financing providing runway into mid-2027 L

GlobeNewswire 6 months ago

PRQR
+6.70%

Performance Overview

Return	PRQR	S&P 500 (^GSPC)
YTD	-27.92%	+2.02%
1-Year	-4.02%	+12.09%
3-Year	+159.16%	+45.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ProQR Therapeutics N.V. (PRQR)

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

New Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR)

ProQR Announces First Quarter 2025 Operating and Financial Results

ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald

ProQR Therapeutics initiated with an Outperform at Evercore ISI

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

ProQR Therapeutics Full Year 2024 Earnings: Misses Expectations

ProQR Announces Year End 2024 Operating and Financial Results

ProQR Therapeutics N.V.'s (NASDAQ:PRQR) largest shareholders are individual investors with 60% ownership, institutions own 17%

Is There An Opportunity With ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 37% Undervaluation?

ProQR Therapeutics announces $8.1M in new funding from RSRT

ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

ProQR Therapeutics price target raised to $8 from $5 at JMP Securities

ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024

ProQR Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

ProQR Therapeutics sees cash runway into mid-2027

ProQR Announces Third Quarter 2024 Operating and Financial Results

Performance Overview